Migraine impairs the auditory protective mechanism: a potential biomarker Authors: Muchen Huang, Guanxia Xiong, Xianren Wang Published: 2026 ABSTRACT AbstractBackgroundMigraine is a prevalent neurological disorder frequently accompanied by auditory symptoms such as tinnitus and hyperacusis. While their associations suggest shared neural mechanisms, objective evidence regarding the specific involvement of brainstem-mediated auditory efferent pathways in migraine remains limited. The medial olivocochlear reflex (MOCR) and the middle ear muscle reflex (MEMR) are two key auditory protective mechanisms, yet their integrity in migraine patients remains to be investigated. This study aimed to evaluate the functional integrity of the MOCR and MEMR pathways in migraine patients with and without comorbid tinnitus.MethodsIn this cross-sectional study, 143 participants were classified into four groups based on strict diagnostic criteria: healthy controls (HC, n = 44), tinnitus-only (T, n = 49), migraine-only (M, n = 25), and migraine with tinnitus (TM, n = 25). Groups were matched for age, sex, and hearing thresholds. All participants underwent comprehensive audiological assessments, including pure-tone audiometry, ipsilateral and contralateral acoustic reflex threshold (ART) testing to assess MEMR function, and distortion-product otoacoustic emissions (DPOAE) with contralateral suppression evaluation to assess MOCR function.ResultsThe migraine group (M) demonstrated significantly elevated contralateral ART (indicating MEMR impairment) at 500 Hz and 1000 Hz (p < 0.001) and globally reduced DPOAE suppression (reflecting MOCR dysfunction) (p < 0.001) compared to healthy controls. The TM group exhibited a similar pattern of MOCR and MEMR dysfunction to the M group, with no significant additive effect from tinnitus comorbidity. A clear gradient of contralateral ART impairment was observed across groups: HC < T < (M ≈ TM). Ipsilateral ART results showed less consistent abnormalities.ConclusionMigraine may be associated with specific dysfunction of brainstem auditory efferent pathways, particularly affecting both MOCR and MEMR systems, independent of peripheral hearing status. The convergent abnormalities in migraine patients with and without tinnitus indicate that auditory efferent disruption may be an intrinsic component of migraine pathophysiology. These findings support the potential of contralateral ART as an objective biomarker of migraine-related auditory pathway involvement, highlighting the clinical value of auditory assessment in migraine management and providing insights for the development of targeted therapeutic strategies.Keywords: Migraine, Tinnitus, CGRP, Acoustic reflex Introduction Migraine is a highly disabling neurological disorder with a global prevalence of approximately 14–15% [1], affecting over 1 billion people [2]. Its clinical manifestations extend far beyond episodic headaches, often accompanied by a range of sensory processing abnormalities [3]. Among these, auditory symptoms such as tinnitus and hyperacusis/phonophobia are particularly prominent: epidemiological surveys show that the prevalence of migraine in tinnitus patients is as high as 36.6%-45%, significantly higher than the 8.4% in the general population [4]; conversely, the hazard ratio (HR) for tinnitus is also significantly increased in migraine patients, reaching 3.30 [5]. Furthermore, some migraine-preventing medications (such as certain beta-blockers and anticonvulsants) have shown therapeutic potential in some tinnitus patients [6]. This strong bidirectional association suggests that the two may share a common underlying neurobiological basis. Of particular note is that 61.5% of patients with vestibular migraine experience auditory symptoms, with tinnitus being the most common manifestation [5]. However, in clinical practice, migraine and hearing impairment are often managed separately, and their comorbidity mechanisms, especially the role of the central nervous system—the brainstem—remain unclear. The pathophysiological process of migraine involves multiple levels, including activation of the trigeminal vascular system, release of neuropeptides such as calcitonin gene-related peptide (CGRP), and central sensitization. These processes may influence auditory system function through pathways such as neurovascular connections and neurotransmitter imbalances [7]. Neuroimaging studies also suggest the presence of central auditory processing abnormalities in migraine patients [8]. This evidence collectively indicates that the two conditions may share underlying neurobiological mechanisms. The brainstem serves as a critical hub where these mechanisms converge [9]. It is both a key center for the descending modulation of migraine pain (involving structures such as the periaqueductal grey (PAG)) [10, 11] and a core node for auditory information processing. Importantly, auditory nuclei within the brainstem, like the superior olivary complex (SOC), are anatomically adjacent to pain-modulatory nuclei [12]. Consequently, migraine-related neural events (such as cortical spreading depression(CSD) or neuroinflammation) may directly disrupt the normal function of these adjacent auditory structures [13]. Furthermore, dysfunction of the brainstem’s monoaminergic systems (e.g., the raphe nuclei and locus coeruleus) may concurrently modulate both pain and auditory sensitivity [14, 15]. This anatomical proximity and functional overlap make the brainstem an ideal nexus for the comorbidity of migraine and auditory symptoms. In the auditory system, two efferent pathways originating from the brainstem—the medial olivocochlear reflex (MOCR) mediated by the medial olivocochlear system (MOCS) and the middle ear muscle reflex (MEMR) mediated by the stapedius muscle reflex arc—are crucial protective mechanisms. The MOCR originates from the SOC, and its fibers project through the olivocochlear tract to the outer hair cells of the contralateral cochlea. Inhibiting hair cell activity sharpens frequency selectivity, improves speech recognition in noise, and reduces the risk of acoustic damage [16, 17]. MOCR function is often assessed by measuring the degree of suppression of distortion-product otoacoustic emissions (DPOAEs) when broadband noise is applied to the contralateral ear (i.e., the contralateral inhibition effect) [18]. MEMR is triggered by loud sound (typically 70–90 dB SPL), causing contraction of the stapedius muscle, which attenuates the sound energy transmitted through the middle ear, protecting the inner ear from damage. Its reflex arc involves the cochlear nucleus, superior olive complex, facial nerve nucleus, and stapedius muscle, and can be measured using the acoustic reflex threshold (ART) [19]. Both pathways rely on brainstem-level integration, especially the contralateral acoustic reflex, which requires midline brainstem coordination; therefore, their functional integrity is a sensitive indicator for assessing brainstem auditory processing capacity. In humans, elevated or absent MEMR thresholds often indicate brainstem or auditory efferent pathway lesions [20, 21], while MOCR dysfunction is associated with hearing difficulties in noise and susceptibility to tinnitus [22]. While there are theoretical grounds for believing that migraines may impair the auditory efferent pathway, empirical research is inconsistent and controversial. Some studies report reduced suppression of OAEs, abnormal ARTs, or decreased OAE amplitudes in migraine patients, despite normal hearing abilities [23, 24], suggesting impaired MOCR or MEMR function. For example, Bolay et al. found reduced contralateral suppression of transient-evoked otoacoustic emissions (TEOAEs) in migraine patients [25]; Hamed et al. reported that the DPOAE and TEOAE amplitudes in the migraine group were significantly lower than those in the control group at certain frequencies, suggesting that DPOAE could be used to potentially screen and identify migraineurs [26]. However, other studies have failed to replicate these results or have found differences only in specific subgroups (such as migraine with aura) [25, 27–29]. Possible reasons for the controversy include: ① high heterogeneity of the study population (e.g., different migraine types, durations, and assessments of attack/interictal periods); ② most studies did not separate patients with simple migraines from those with migraine comorbid tinnitus, making it impossible to distinguish whether the abnormalities were caused by migraines themselves or by the additive effect of tinnitus; ③ inconsistent assessment methods (e.g., different frequencies and intensities of acoustic stimulation used); ④ inadequate matching of control groups (e.g., mismatched age and hearing thresholds). The more fundamental controversy lies in whether tinnitus is a concomitant phenomenon of the migraine pathology process (i.e., a direct manifestation of brainstem dysfunction) or an independent comorbidity superimposed on migraine. If tinnitus is simply an associated symptom, then patients who experience both migraines and tinnitus should not have a more severe dysfunction of the auditory efferent system than those who suffer from migraines alone. If this is not the case, it would support the superposition model. Additionally, routine hearing tests, such as pure-tone audiometry, often appear normal in these patients, even though their auditory efferent function may be impaired at a subclinical level. Therefore, there is an urgent clinical need for the development of objective biomarkers that target the efferent pathway. To clarify the mentioned controversies, this study was designed as a rigorous cross-sectional study. We systematically included four groups of age-, sex-, and hearing threshold-matched subjects: healthy controls (HC), tinnitus alone (T), migraine alone (M), and migraine with tinnitus (TM). By comprehensively assessing pure-tone hearing threshold, ipsilateral/contralateral ARTs, DPOAE, and their contralateral inhibition effect, we aimed to systematically explore the following three progressive scientific questions: This study aimed to investigate whether migraine is specifically associated with impaired function of the brainstem auditory efferent pathways (MOCR and MEMR). Specifically, by comparing the differences in ARTs and DPOAE suppression between the M and HC groups, we examined whether the migraine central sensitization model might extend to the auditory modulation pathway. This study aimed to investigate whether migraine is specifically associated with impaired function of the brainstem auditory efferent pathways (MOCR and MEMR). Specifically, by comparing the differences in ARTs and DPOAE suppression between the M and HC groups, we examined whether the migraine central sensitization model might extend to the auditory modulation pathway. We further asked whether comorbid tinnitus exacerbates this impairment. By comparing the functional profiles between the TM and M groups, we sought to determine whether tinnitus exerts an additive effect, thereby shedding light on its pathological origin. We further asked whether comorbid tinnitus exacerbates this impairment. By comparing the functional profiles between the TM and M groups, we sought to determine whether tinnitus exerts an additive effect, thereby shedding light on its pathological origin. Can auditory reflexes (such as ARTs) have potential as objective biomarkers for identifying migraine-related tinnitus subtypes? This study aims to evaluate the clinical translational value of these indicators by analyzing their correlation with clinical symptoms. Can auditory reflexes (such as ARTs) have potential as objective biomarkers for identifying migraine-related tinnitus subtypes? This study aims to evaluate the clinical translational value of these indicators by analyzing their correlation with clinical symptoms. The results of this study are expected to provide new physiological evidence to elucidate the comorbidity mechanism of migraine and tinnitus, and to offer supportive evidence for identifying this potential migraine-related tinnitus subtype and for developing precision treatment strategies. From a broader perspective, understanding the role of the brainstem auditory efferent pathway in the pathophysiology of migraine not only helps reveal the universal mechanisms underlying sensory processing abnormalities but also opens new avenues for exploring auditory symptoms in other primary headache disorders (such as cluster headaches). Future research can further combine neuroimaging and neurophysiological techniques to dynamically track changes in brainstem functional status during migraine cycles, thereby suggesting new directions for the early diagnosis and intervention of migraine. Methods This cross-sectional study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University ([2020]062). In accordance with the Declaration of Helsinki, all participants provided written informed consent prior to data collection. Participants were recruited consecutively from the Departments of Otolaryngology and Neurology at the First Affiliated Hospital of Sun Yat-sen University between March and August 2025. Based on strict diagnostic and exclusion criteria, participants were divided into the following four groups. All subjects underwent pure-tone audiometry, ipsilateral/contralateral AR testing, distortion product otoacoustic emissions (DPOAE), and contralateral suppression of DPOAE. The definitions of the four groups are as follows: Healthy Control Group: No history of tinnitus or headache. Healthy Control Group: No history of tinnitus or headache. Tinnitus-only group: Chronic subjective tinnitus lasting ≥ 3 months, without a history of migraine or other secondary headaches. Tinnitus-only group: Chronic subjective tinnitus lasting ≥ 3 months, without a history of migraine or other secondary headaches. Migraine-only group: Diagnosed with migraine without aura or with aura according to ICHD-3 criteria, without a history of tinnitus. Migraine-only group: Diagnosed with migraine without aura or with aura according to ICHD-3 criteria, without a history of tinnitus. Migraine with Tinnitus group: Meeting the diagnostic criteria for both the tinnitus-only group and the migraine-only group. Migraine with Tinnitus group: Meeting the diagnostic criteria for both the tinnitus-only group and the migraine-only group. Inclusion criteria Age 18–60 years (to reduce the likelihood of subclinical presbycusis affecting high-frequency thresholds). Age 18–60 years (to reduce the likelihood of subclinical presbycusis affecting high-frequency thresholds). Clinical normal hearing abilities with mean pure-tone hearing threshold (500, 1000, 2000, 4000 Hz) ≤ 25 dB HL in both ears. Clinical normal hearing abilities with mean pure-tone hearing threshold (500, 1000, 2000, 4000 Hz) ≤ 25 dB HL in both ears. Normal middle ear function confirmed by bilateral Type A tympanogram. Normal middle ear function confirmed by bilateral Type A tympanogram. Exclusion criteria History of middle ear disease (e.g., tympanic membrane perforation, acute or chronic otitis media, tympanic effusion). History of middle ear disease (e.g., tympanic membrane perforation, acute or chronic otitis media, tympanic effusion). History of noise-induced hearing loss, organic nervous system disease (e.g., acoustic neuroma, multiple sclerosis), or severe mental illness. History of noise-induced hearing loss, organic nervous system disease (e.g., acoustic neuroma, multiple sclerosis), or severe mental illness. History of ototoxic drug use or prolonged noise exposure. History of ototoxic drug use or prolonged noise exposure. Imaging findings suggestive of organic lesions in the inner ear or central nervous system. Imaging findings suggestive of organic lesions in the inner ear or central nervous system. Audiological assessment Pure-tone audiometry Using a Madsen Conera clinical audiometer (GN Otometrics, Denmark), hearing thresholds were measured in a soundproof room. The test frequencies covered 250, 500, 1000, 1500, 2000, 400, and 8000 Hz (3000 and 6000 Hz were added for tinnitus patients). The testing method employed the 10-to-5 method, operated by a professional, who adjusted the sound intensity in 5 dB steps and recorded the lowest audible threshold (dB HL). The PTA is the average hearing threshold at the four frequencies of 500, 1000, 2000, and 4000 Hz. Acoustic reflex test Tympanograms and acoustic reflex tests were performed using a GSI TympStar Pro middle ear analyzer (Grason-Stadler, USA). ART: Using pure tones of 500 Hz and 1000 Hz as stimuli, starting at 80 dB HL, the intensity was increased in 5 dB steps, and the minimum stimulus intensity that caused a change in acoustic impedance ≥ 0.03 ml was recorded. If there was no response at 120 dB HL, it was recorded as 125 dB HL for statistical analysis. DPOAE An Interacoustics Titan system was used. Probe calibration was performed before testing. Using f2 frequency as the core (0.5, 1, 1.5, 2, 3, 4, 6, 8 kHz), stimulation parameters of f2/f1 = 1.22, L1 = 65 dB SPL, and L2 = 55 dB SPL were employed to record the amplitude of the 2f1-f2 distortion product. Contralateral Suppression Testing: After the baseline DPOAE test, 60 dB SPL white noise was applied to the contralateral ear via an in-ear headphone, while DPOAE recording was repeated. The suppression amount (ΔDP) was calculated as the difference between the baseline amplitude and the amplitude under suppression at the same frequency. To minimize the potential influence of migraine attack-related excitability fluctuations on brainstem reflexes, all participants in the migraine groups (M and TM) were tested strictly during the interictal phase. This was defined as a period of at least 72 h after the cessation of a previous migraine attack and at least 24 h before the onset of any prodromal symptoms of a subsequent attack. Statistical analysis SPSS 29.0 and GraphPad Prism 10.0 software were used for statistical analysis. Quantitative data were expressed as mean ± standard deviation. The normality of distribution for all continuous variables was assessed using the Shapiro-Wilk test. T-tests for normally distributed quantitative data, and Mann-Whitney U tests for non-normally distributed quantitative data. Analysis of variance (ANOVA) was used to compare continuous variables among the four groups, and Tukey’s HSD test was used for post hoc comparisons. Chi-square test was used for comparisons of categorical variables. Statistical significance was set at p < 0.05 (two-sided test). Results This study included 143 participants, who were divided into four groups according to diagnostic criteria: tinnitus with migraine (TM, n = 25), migraine only (M, n = 25), tinnitus only (T, n = 49), and a healthy control group (HC, n = 44). The groups were well-matched in age and sex distribution. Participants were aged 18–60 years, and there was no significant difference in mean age among the four groups (p > 0.05). Female participants were predominant in each group, consistent with the epidemiological characteristics of migraine in the population. Regarding clinical characteristics, the mean duration of tinnitus in the TM group was (1.63 ± 2.19) years, and in the T group it was (2.00 ± 2.50) years, with similar distributions of tinnitus location (left, right, or bilateral) between the two groups. The mean duration of migraine in the M group was (4.90 ± 3.44) years, and in the TM group it was (9.21 ± 8.94) years, respectively. The two groups showed high consistency in the distribution of migraine subtypes (with and without aura), headache location, headache nature (throbbing, oppressive, etc.), and accompanying symptoms (vertigo, nausea and vomiting, phonophobia, photophobia, etc.), as detailed in Table 1. Pure-tone audiometry results were matched for all participants (Table 2; Fig. 1), ruling out the potential influence of peripheral hearing loss on the core results. Table 1Demographic and clinical characteristics of the study participantsDemographic and clinical characteristicsTMMTHC Male/female 9/166/1927/2214/30 Age, years 21–60 (37.09 ± 10.86)22–55 (34.79 ± 8.24)20–60 (33.23 ± 10.21)18–58 (37.70 ± 14.02)Course of Tinnitus, years0.33-10 (1.63 ± 2.19)0.25-10 (2.00 ± 2.50) Localization of Tinnitus Left8 (32%)13 (26.53%) Right7 (28%)15 (30.61%) Bilateral10 (40%)21 (42.86%) MO/MA 16/920/5 Sensory Aura2 (22.22%)0 Abnormal Neurological Function3 (33.34%)2 (40%) Speech Aura2 (22.22%)1 (20%) Visual Aura2 (22.22%)2 (40%) Course of Migraine 1–30(9.21 ± 8.94)1–15(4.90 ± 3.44) Location of headache The left side only7 (28%)6 (24%) The right side only6 (24%)4 (16%) Bilateral(Occurs simultaneously or alternately on both sides)7 (28%)10 (40%) Parietal or Occipital5 (20%)5 (20%) Nature of the Headache Throbbing/Pulsating9 (36%)10 (40%) Pressure-like pain10 (40%)10 (40%) Sharp4 (16%)4 (16%) Dull2 (8%)1(4%) Accompanying Symptoms Vertigo15 (60%)16 (64%) Nausea and Vomiting10 (40%)11 (44%) Phonophobia16 (64%)20 (80%) Photophobia18 (72%)20 (80%) Tearing/Rhinorrhea/Conjunctival Injection/Ptosis6 (24%)4 (16%) Clinical Management Parameters Number of days per month2.28 ± 1.512.12 ± 1.51 VAS score5.24 ± 1.675.08 ± 1.47 Treatment (n)Ibuprofen(13)/Paracetamol (5)/ None(7)Ibuprofen(15)/Paracetamol (1)/ None(9)Note. Data are presented as n, n (%), mean ± standard deviation, as appropriate. TM, Tinnitus with Migraine group; M, Migraine-only group; T, Tinnitus-only group; HC, Healthy Control group; MO, Migraine without aura; MA, Migraine with aura Demographic and clinical characteristics of the study participants Bilateral (Occurs simultaneously or alternately on both sides) Note. Data are presented as n, n (%), mean ± standard deviation, as appropriate. TM, Tinnitus with Migraine group; M, Migraine-only group; T, Tinnitus-only group; HC, Healthy Control group; MO, Migraine without aura; MA, Migraine with aura Table 2Pure-tone audiometry thresholds across test frequenciesFrequency (Hz)Pure Tone Average Thresholds (PTA, dB)HCTMTM12516.4 ± 7.516.7 ± 7.213.8 ± 6.416.0 ± 6.525011.5 ± 8.014.1 ± 6.815.0 ± 6.512.4 ± 7.150012.8 ± 6.114.4 ± 5.414.5 ± 5.215.0 ± 5.2100013.3 ± 5.212.9 ± 5.413.8 ± 5.313.9 ± 5.0200013.1 ± 7.413.8 ± 5.811.6 ± 5.612.1 ± 7.3300014.8 ± 8.216.5 ± 8.115.4 ± 7.313.1 ± 7.8400011.7 ± 7.414.4 ± 8.512.1 ± 7.411.6 ± 7.5600023.5 ± 11.528.9 ± 13.620.7 ± 9.420.0 ± 11.7800017.5 ± 14.620.3 ± 13.613.0 ± 9.020.3 ± 18.3 Pure-tone audiometry thresholds across test frequencies Comparison of pure-tone audiometry thresholds across study groups. The pure-tone hearing thresholds (dB HL) for the Healthy Control (HC), Tinnitus-only (T), Migraine-only (M), and Tinnitus with Migraine (TM) groups at frequencies from 125 Hz to 8000 Hz. Error bars represent standard deviation For contralateral ART, significant inter-group differences were found at 500 Hz and 1000 Hz (both p < 0.05). At 500 Hz, post-hoc tests revealed the following hierarchy: HC < T < (M, TM). Specifically, the HC group had lower ART than the T (MD = -5.2 dB, p = 0.035), M (MD = -11.8 dB, p < 0.001), and TM groups (MD = -10.8 dB, p < 0.001). The T group had lower ART than the M (MD = -6.5 dB, p = 0.003) and TM groups (MD = -5.5 dB, p = 0.038). No difference was found between the M and TM groups (MD = 1.0 dB, p = 0.960). The pattern was similar at 1000 Hz: HC < T < (M, TM). (HC vs. T: MD = -6.2 dB, p = 0.008; HC vs. M: MD = -14.2 dB, p < 0.001; HC vs. TM: MD = -12.0 dB, p < 0.001; T vs. M: MD = -8.0 dB, p < 0.001; T vs. TM: MD = -5.8 dB, p = 0.026; M vs. TM: MD = 2.2 dB, p = 0.719). The effect size for the overall main effect of group on contralateral ART was large, as indicated by a partial eta-squared (η²) of 0.236. Post hoc pairwise comparisons further revealed substantial effect sizes for the key group differences. Compared to healthy controls (HC), both the migraine-only (M) and migraine-with-tinnitus (TM) groups showed large impairments in contralateral ART at both 500 Hz (Cohen’s d = 1.28 and 1.17, respectively) and 1000 Hz (Cohen’s d = 1.50 and 1.31, respectively). When compared to the tinnitus-only (T) group, the M group exhibited a large effect at 1000 Hz (Cohen’s d = 0.85) and a medium effect at 500 Hz (Cohen’s d = 0.77), while the TM group showed medium effects compared to the T group at both frequencies (Cohen’s d = 0.66). For ipsilateral ART, group differences were less consistent. At 500 Hz, the HC group had lower thresholds than the M (MD = -11.7 dB, p < 0.001) and TM groups (MD = -9.2 dB, p = 0.020), and the T group was lower than the M (MD = -10.6 dB, p = 0.001) and TM groups (MD = -8.0 dB, p = 0.047). No differences were found between HC and T (p = 0.978) or M and TM (p = 0.840). At 1000 Hz, only the difference between the T and M groups was significant (MD = -7.4 dB HL, p = 0.043) (Table 3; Fig. 2). Table 3Acoustic reflex thresholds and absence rates in the study groupsFrequencies (kHz)Number of cases without reflex (n (%))Thresholds (M ± SD) (dB HL)TMMTHCTMMTHCIpsilateral0.56 (24.0)10 (40.0)3 (6.12)5 (11.36)99.9 ± 15.8a, b102.4 ± 17.8a, b91.8 ± 10.190.7 ± 13.713 (12.0)6 (24.0)4 (8.16)2 (4.55)94.3 ± 12.398.9 ± 15.3b91.5 ± 11.794.1 ± 12.8Contralateral0.510 (40.0)13 (52.0)10 (20.41)4 (9.09)116.4 ± 7.·1a, b117.6 ± 7.5a, b110.9 ± 9.7a105.8 ± 9.019 (36.0)12 (48.0)6 (12.24)4 (9.09)115.3 ± 9.9a, b117.4 ± 8.2a, b109.5 ± 11.4a103.3 ± 10.3Note. aSignificant difference compared to the Healthy Control (HC) group. bSignificant difference compared to the Tinnitus-only (T) group Acoustic reflex thresholds and absence rates in the study groups Note. aSignificant difference compared to the Healthy Control (HC) group. bSignificant difference compared to the Tinnitus-only (T) group Comparison of acoustic reflex thresholds across study groups. (a) Contralateral and (b) ipsilateral acoustic reflex thresholds (ARTs, in dB HL) at 500 Hz and 1000 Hz probe tones in the healthy control group (HC), the tinnitus-only group (T), the migraine-only group (M), and the tinnitus-migraine-combined group (TM). Data are expressed as mean ± standard deviation (error bar). Statistical significance was determined using ANOVA and Tukey’s post hoc test. An asterisk indicates a significant difference (* p < 0.05, ** p < 0.01, *** p < 0.001). A horizontal line with an asterisk indicates a significant difference between groups Baseline DPOAE amplitudes were generally lower in the T, M, and TM groups compared to the HC group. At 1000 Hz, amplitudes in the HC group were higher than in the T (MD = 3.1 dB, p < 0.001) and M groups (MD = 3.0 dB, p = 0.011), but not the TM group (p > 0.05). At 2000 Hz, HC was higher than T (MD = 3.6 dB, p < 0.001) and M (MD = 3.8 dB, p < 0.001). At 4000 Hz, HC was higher than T (MD = 3.6 dB, p < 0.001), and the T group was higher than the TM group (MD = 3.0 dB, p = 0.013) (Table 4; Fig. 3). Table 4Distortion product otoacoustic emissions (DPOAE) amplitudesFrequency (Hz)DPOAE (dB)HCTMTM5006.2 ± 4.24.6 ± 4.56.0 ± 4.65.9 ± 4.0100010.0 ± 5.56.8 ± 5.7a7.0 ± 5.7a8.7 ± 5.0150011.2 ± 5.58.6 ± 5.0a9.3 ± 4.810.2 ± 4.820009.2 ± 5.75.6 ± 5.0a5.5 ± 5.2a7.6 ± 4.430005.5 ± 5.32.1 ± 4.9a2.0 ± 5.2a3.8 ± 5.040006.7 ± 5.73.0 ± 5.8a4.7 ± 5.36.1 ± 5.5bNote. aSignificant difference compared to the Healthy Control (HC) group. bSignificant difference compared to the Tinnitus-only (T) group Distortion product otoacoustic emissions (DPOAE) amplitudes Note. aSignificant difference compared to the Healthy Control (HC) group. bSignificant difference compared to the Tinnitus-only (T) group Comparison of baseline distortion product otoacoustic emission (DPOAE) amplitudes across study groups. Baseline DPOAE amplitudes (dB SPL) for the Healthy Control (HC), Tinnitus-only (T), Migraine-only (M), and Tinnitus with Migraine (TM) groups across test frequencies (500–4000 Hz). Error bars represent standard deviation The contralateral suppression of DPOAE (ΔDP) was significantly reduced in all patient groups (T, M, TM) compared to the HC group across all frequencies (500–4000 Hz; all p < 0.001). For instance, at 500 Hz, the suppression amplitude in the HC group was significantly greater than that in the T group (MD = 4.9 dB, p < 0.0001), M group (MD = 5.8 dB, p < 0.0001), and TM group (MD = 4.7 dB, p < 0.0001). However, there were no significant differences in ΔDPOAE among the three patient groups (T, M, TM) at any frequency (all p > 0.05) (Table 5; Fig. 4). Table 5Contralateral suppression magnitude of DPOAEs (Δ DP)Frequency (Hz)△DP (dB)HCTMTM5004.5 ± 2.3-0.4 ± 2.1a-1.3 ± 2.3a-0.2 ± 4.0a10003.5 ± 1.70.2 ± 2.4a0.6 ± 2.1a0.5 ± 2.6a15002.8 ± 1.50.6 ± 1.8a0.1 ± 1.3a0.9 ± 1.7a20002.8 ± 1.50.7 ± 2.2a0.8 ± 1.8a1.3 ± 1.8a30002.3 ± 1.50.4 ± 1.6a-0.2 ± 2.2a0.5 ± 1.6a40002.7 ± 2.20.2 ± 1.3a0.5 ± 2.0a0.2 ± 1.7aNote. aSignificant difference compared to the Healthy Control (HC) group Contralateral suppression magnitude of DPOAEs (Δ DP) Note. aSignificant difference compared to the Healthy Control (HC) group Contralateral inhibition of DPOAE across study groups. The contralateral suppression of distortion-product otoacoustic emissions (DPOAE) is shown for the Healthy Control (HC), Tinnitus-only (T), Migraine-only (M), and Tinnitus with Migraine (TM) groups across test frequencies (500–4000 Hz). The y-axis represents the change in DPOAE level (ΔDP in dB SPL). Data are expressed as mean ± standard deviation (error bar). Statistical significance was determined by ANOVA and Tukey’s post hoc test. Asterisks indicate a significant difference (*p < 0.05, **p < 0.01, ***p < 0.001) Discussion This study systematically evaluated the MOCR and the MEMR in four strictly matched groups (HC, T, M, TM). The findings revealed that: (1) the M group showed significant abnormalities in both contralateral ARTs and contralateral inhibition of DPOAE, indicating simultaneous impairment of both the MOCR and MEMR pathways; (2) the auditory efferent function impairment in the TM group did not have a significant additive effect compared to the M group. All subjects had normal pure-tone hearing thresholds, suggesting that the aforementioned functional impairments were not due to peripheral auditory organ lesions, but rather more consistent with a centrally originating dysregulation stemming from brainstem dysfunction. These results support the view that tinnitus, in this context, may not represent an independent comorbidity of migraine, but rather a clinical manifestation potentially linked to the auditory system involvement within the migraine pathology, thereby providing relevant physiological evidence for considering the clinical subtype of “migraine-related tinnitus.” Although TEOAE and DPOAE are both commonly used evoked otoacoustic emission (EOAE) techniques for assessing cochlear function [30], this study chose DPOAE as the primary detection method. TEOAE reflects the activation state of the entire cochlea and has good response characteristics in the mid-frequency range (1–4 kHz); while DPOAE can assess cochlear function in a frequency-specific manner, covering a wider frequency range [18, 26, 31]. In this study, we focused on results in the 500–4000 Hz range, as the low-frequency range (e.g., below 1 kHz) is easily affected by environmental noise, thereby reducing measurement reliability [32]. This method selection is consistent with the study by Albanese et al., which showed that, in migraine patients, only DPOAE (not TEOAE) showed statistically significant differences [33], suggesting that DPOAE may be more sensitive in detecting subtle cochlear dysfunction. Furthermore, we used the DPOAE response amplitude rather than the signal-to-noise ratio (SNR) as the quantitative indicator. While the SNR is often used to detect a signal, an increase in its value may result from reduced background noise rather than an actual increase in response; thus, it is not the optimal parameter for assessing changes in cochlear function [30]. Amplitude, on the other hand, more directly reflects the activity intensity of outer hair cells, providing a more robust basis for evaluating cochlear function in this study. Localization of auditory efferent pathway dysfunction associated with migraine: shared and distinct pathways Migraine is a complex neurological disorder characterized by abnormal cortical excitability that can affect sensory processing, including within the auditory domain. Common auditory manifestations include tinnitus, ear fullness, and phonophobia [34]. The functional integrity of auditory efferent pathways, particularly the MOCR and MEMR, can be objectively assessed. These reflexes involve brainstem circuits and peripheral effectors, and are assessed using OAE and ART, respectively. Studying these pathways in migraine provides an important window into understanding underlying auditory brainstem dysfunction. From a neuroanatomical perspective, the MOCR and MEMR reflex arcs share and operate independently within the brainstem. The MEMR depends on the integrity of cranial nerves VII and VIII, the brainstem, and the middle ear [35], while the MOCR involves cranial nerve VIII, the SOC, medial olive cochlear neurons, cochlear hair cells, and the middle ear [36]. The contralateral MOCR and MEMR pathways are thought to originate in the brainstem, with their key bifurcation point proposed to be located at the SOC. The MOCR pathway projects from the superior colliculus to the outer hair cells (OHC) of the cochlea via the MOC, while the MEMR pathway extends from the motor neurons of the SOC to the facial nerve nucleus, thereby innervating the stapedius muscle. The core finding of this study—a general decrease in contralateral DPOAE inhibition amplitude without intergroup gradient, while contralateral ART showed a clear gradient difference (HC < T < M ≈ TM)—provides crucial clues for hypothesizing lesion localization. The pervasive abnormality in DPOAE inhibition suggests that migraine predominantly affects the shared pathways of MOCR and MEMR, potentially at the level of integrative function at the SOC level or its upstream inputs. This widespread inhibition may stem from the non-specific effects of migraine-related trigeminal vascular system activation and central sensitization on the brainstem network. The difference in gradient of contralateral ART suggests that migraine, in addition to shared pathway damage, may more specifically involve a distinct segment of the MEMR pathway (i.e., the segment from the SOC to the facial nucleus-stapedius muscle). The reflex arc of contralateral ART needs to cross the brainstem midline, involving complex cross-modal integration, and is therefore particularly sensitive to central lesions. This finding aligns with clinical observations: a significant case series by Birkenbeuel et al. provides clinical evidence supporting a link between migraine pathophysiology and stapedius muscle dysfunction, showing that stapedius myoclonus (an objective tinnitus) can respond to preventive migraine treatment [37]. Therefore, the abnormal MEMR threshold gradient we observed may reflect the impact of migraine on the subclinical level of the stapedius muscle control pathway, which may be a different manifestation of the same pathophysiological spectrum as stapedius myoclonus. Acetylcholine (ACh) is crucial for the proper functioning of the MOC system [38, 39]. Experimental evidence suggests that CGRP can promote phosphorylation of ACh receptors in the inner ear, positioning it as a potential inhibitory modulator of cholinergic signaling [40]. Previous studies have proposed that elevated CGRP activity in patients with migraine and phonophobia could impair OAE inhibition by interfering with ACh activity at the cochlear synapse [28]. This provides a potential mechanistic link between CGRP and auditory efferent dysfunction. Furthermore, CGRP has been implicated in the potential molecular mechanisms underlying both tinnitus and migraine [41]. Clinical observations align with this concept, as chronic migraine patients often report exacerbations of tinnitus, and CGRP monoclonal antibodies have been shown to alleviate headache and hyperacusis symptoms in some patients [42]. However, this interpretation requires further investigation to be substantiated. We also hypothesize that the phonophobia symptoms in migraine patients may be related to abnormal AR. The phonophobia in migraineurs may be due to a lower hearing threshold and higher excitability of brainstem neurons [9]. CGRP is known to amplify sensory hypersensitivity and form a feedback loop that maintains central sensitization [43]. CGRP has also been shown to be expressed in stapedius neurons [44]. As a protective mechanism, the AR reduces the mechanical transmission of loud sound stimuli to the inner ear; its dysfunction could therefore exacerbate the experience of phonophobia. The lack of an additive effect in comorbid tinnitus supports the concept of a “migraine-related tinnitus” profile A key observation in this study is the general absence of significant differences in most auditory physiological parameters between the TM and M groups. This result is significant for understanding the relationship between migraine and tinnitus. If tinnitus were an independent comorbidity, one might expect to see more severe physiological impairment in the TM group compared to the M group, reflecting an “additive effect.” However, the degree of impairment was highly similar between the two groups. This phenomenon can be compared with recent findings on other auditory symptoms. For example, Ozkar and Soylemez reported that the presence of phonophobia in migraine patients did not significantly affect their temporal or frequency discrimination abilities [45]. These findings collectively suggest that the physiological basis of certain auditory symptoms coexisting with migraine may be more related to the central nervous system function of migraine itself, rather than representing an independent, additive pathological process. This interpretation aligns with the concept of “central sensitization.” The excitation/inhibition imbalance within the central nervous system associated with migraine may lower the activation threshold and increase the gain of the auditory pathway, potentially amplifying spontaneous neural activity to a perceptual level experienced as tinnitus. Thus, in the TM group, tinnitus and auditory efferent dysfunction may share a common upstream driver—namely, migraine-mediated brainstem dysregulation. Together, these physiological observations provide supportive evidence for considering such patients under a “migraine-related tinnitus” profile. From a clinical perspective, this framework implies that for patients presenting with both migraine and tinnitus, management strategies could prioritize addressing the migraine and its associated central sensitization, alongside or prior to targeting tinnitus as an isolated entity. Such an approach might help streamline clinical management and reduce the burden of multiple, parallel treatment pathways. Contralateral acoustic reflex threshold: a potential biomarker for migraine-related auditory pathway dysfunction Strict exclusion criteria effectively controlled for peripheral confounds, thereby focusing the investigation on retrocochlear dysfunction. Beyond established factors like aging and peripheral hearing loss, our results showed that contralateral ART was significantly higher in the patient group than in the healthy control group, while ipsilateral ART results were less consistent. Neuroanatomical differences in the reflex pathway may explain this selective impairment phenomenon. The contralateral auditory reflex relies on signal transmission across the brainstem midline, involving a cross-modal pathway from the superior colliculus to the contralateral facial nucleus. This longer, integrated pathway is thought to be more susceptible to central nervous system disturbances (such as brainstem ischemia, multiple sclerosis) [46] or neurotransmitter imbalances [47]. The ipsilateral auditory reflex relies primarily on a short, non-crossing pathway on the same side, making it more susceptible to peripheral factors such as middle ear dysfunction or localized facial nerve lesions [48]. These anatomical considerations suggest that contralateral auditory reflex abnormalities may serve as a sensitive indicator of central auditory dysfunction. Specifically, in the absence of middle ear lesions, normal hearing levels coupled with an absent ART could indicate possible retrocochlear involvement, such as reduced neural conduction efficiency or altered neuronal reactivity at the auditory brainstem level [49]. The observed ART elevation in the M and TM groups aligns with migraine as a disorder of central excitability [50], but introduces a nuance. While upregulation of central gain is often associated with increased auditory pathway excitability [51], our findings suggest the regulation in migraine may be more complex. For instance, a study by Hutchison et al. demonstrated that after short-term unilateral auditory deprivation, the ART of young people with normal hearing significantly decreased by approximately 8–10 dB, providing direct objective evidence of adaptive upregulation of central gain at the brainstem level [52]. This suggests that in the pathological state of migraine, the regulation of central gain may be more complex than a simple “volume increase.” The central nervous system of migraine patients may be in a state of sensory processing dysfunction [7]; their characteristic central sensitization and trigeminal vascular system activation may, by altering neural integration or the inhibitory-excitation balance within the brainstem reflex arc, actually reduce its synchronized firing capacity or increase the activation threshold, thus requiring higher intensity stimuli to elicit the reflex. A major advantage of this study is its inclusion of diverse patient populations (T, M, TM), enabling multidimensional and objective assessment. Importantly, we demonstrated that a simple, widely used clinical test—the contralateral ART—can help identify dysfunction of the brainstem auditory efferent pathway associated with migraine. Compared to methods that rely on more complex instruments, this approach uses routine clinical equipment, improving the practicality and accessibility of assessing this pathophysiological aspect. For clinicians, incorporating contralateral ART assessment when evaluating migraine patients with auditory symptoms may provide an objective indication of potential central auditory processing dysfunction. This offers supportive evidence that such dysfunction is a relevant component of the migraine disease process, which could inform the development of more comprehensive management strategies that consider the potential involvement of the auditory pathway. Limitations and future directions This study has several limitations that should be considered when interpreting the results. First, the cross-sectional study design cannot establish a causal relationship between migraine and observed auditory efferent dysfunction. Second, the relatively small sample size, particularly in the M and TM groups, limits the statistical power of in-depth subgroup analyses (e.g., based on migraine duration or aura phenotype). Furthermore, the lack of stratification by migraine subtype may mask potential heterogeneity effects. Finally, the lack of simultaneous electrophysiological measurements, such as electrocochleography (ECochG) and auditory brainstem response (ABR), limits our ability to further pinpoint the specific locations of neural dysfunction within the auditory pathway (e.g., synaptic lesions and demyelinating lesions). These limitations point to directions for future research. To address temporal uncertainties, longitudinal studies are needed to track dynamic changes in auditory efferent markers, such as ART and DPOAE inhibition levels, across migraine cycles, attack frequencies, and treatment interventions. Such studies could help evaluate whether improvements in migraine burden — including through treatments like CGRP-targeting agents — are accompanied by a normalization of auditory efferent function and a reduction in tinnitus symptoms. If observed, such a correlation would lend weight to the hypothesis that tinnitus may often arise as a downstream manifestation of migraine pathophysiology rather than an independent comorbidity. Furthermore, future studies incorporating validated measures of hyperacusis and tinnitus severity are warranted to explore potential correlations with the degree of auditory efferent dysfunction observed here. Additionally, integrating animal models could further explore potential neural pathways, including those involving neuropeptides such as CGRP, that might regulate the MOCR and MEMR arcs. Finally, to facilitate clinical translation, efforts should be made to establish hearing screening protocols for migraine patients and incorporate ART into routine assessments. ART could serve as an objective screening tool for patients with migraine and concurrent auditory symptoms (especially refractory tinnitus or hyperacusis). In these cases, identifying auditory efferent dysfunction could help confirm the neurological basis of these sensory abnormalities and guide the development of targeted treatment strategies. Future studies combining dynamic monitoring of biochemical markers with functional neuroimaging may provide a more comprehensive profile of comorbid neurobiology and explore potential associations with molecules like CGRP, potentially offering objective biomarkers for assessing treatment efficacy. Conclusion This cross-sectional study demonstrates a significant association between migraine and concurrent dysfunction of the two primary brainstem-mediated auditory efferent pathways—the MEMR and MOCR—independent of peripheral hearing loss. The finding of similarly elevated contralateral acoustic reflex thresholds and reduced otoacoustic emission suppression in migraine patients, with or without comorbid tinnitus, suggests that auditory efferent disruption may be an intrinsic neurophysiological correlate of migraine. The lack of an additive deficit in the comorbid group further indicates that, in this cohort, tinnitus likely manifests as a symptomatic consequence of the shared migraine pathophysiology rather than an independent disorder. Converging evidence from the literature, including the potential involvement of neuropeptides such as CGRP in modulating central auditory gain, provides a plausible framework for these observations, though direct mechanistic validation remains a goal for future research. Importantly, the contralateral ART emerges from this work as a simple, objective, and clinic-ready measure that holds promise as a candidate biomarker for identifying and quantifying migraine-related auditory pathway involvement. These findings underscore the importance of incorporating auditory functional assessments into the comprehensive management of migraine, particularly for patients presenting with auditory hypersensitivity, and pave the way for developing more targeted therapeutic strategies. Author contributions M. H. conceived and designed the study, performed data analysis and drafted the manuscript. G. X. and X. W. supervised the study, contributed to the study design, analysis, and interpretation of results. All authors reviewed the manuscript. Funding This research was supported by grants from the Natural Science Fund of Guangdong Province (2024A1515010755). Data availability The datasets generated for this study are available on request to the corresponding author. Declarations Ethical approval The ethics committee of the First Affiliated Hospital of Sun Yat-sen University (No. [2020]062) reviewed and approved this study. In accordance with the Declaration of Helsinki, all participants provided written informed consent before data collection. Requests for reprints Xianren Wang at the Department of Otolaryngology, the first affiliated hospital of Sun Yat-sen University, Guangzhou 510080, China. E-mail: wangxren@mail.sysu.edu.cn. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Guanxia Xiong, Email: xguanx@mail.sysu.edu.cn. Xianren Wang, Email: wangxren@mail.sysu.edu.cn. References Associated Data Data Availability Statement The datasets generated for this study are available on request to the corresponding author.